Diabetes, Vol 45, Issue 1 91-100, Copyright © 1996 by American Diabetes Association

ARTICLES

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes

AC Moses, SC Young, LA Morrow, M O'Brien and DR Clemmons
Division of Endocrinology, Charles A. Dana Research Institute, Harvard-Thorndike Laboratories, Beth Israel Hospital, Boston, MA 02215, USA.

Insulin resistance is a major factor in the pathophysiology of type II diabetes and a major impediment to successful therapy. The identification of treatments that specifically target insulin resistance could improve diabetes management significantly. Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes. A total of 12 patients with type II diabetes were recruited for the study. Subcutaneous administration of rhIGF-I (100 micrograms/kg b.i.d.) significantly lowered blood glucose. Fructosamine declined from 369 to 299 mumol/l by 3 weeks of administration and then declined further to 271 at the end of 5 weeks. Glycosylated hemoglobin, which was 10.4% pretreatment, declined to 8.1% at the end of therapy. Mean 24-h blood glucose during a modal day was 14.71 +/- 4.5 mmol/l pretreatment and declined to 9.1 +/- 3.21 mmol/l by the end of treatment. These improvements in glycemia were associated with a decrease in serum insulin levels. Mean insulin concentrations declined from 108.0 to 57.0 pmol/l during the modal day measurements and from 97.2 to 72.0 pmol/l during the mixed-meal tolerance test. Changes in glycemia were accompanied by a marked increase in insulin sensitivity. The insulin sensitivity index (SI) calculated from a frequently sampled intravenous glucose tolerance test (FSIVGTT) after the method of Bergman et al. (Bergman RN, Finegold DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86, 1985) increased 3.4-fold. Furthermore, the improvement in glycemic control was accompanied by a change in body composition with a 2.1% loss in body fat as calculated by dual energy x-ray absorptiometry without change in total body weight. Significant side effects were present in some subjects, although nine subjects were able to complete at least 4.5 weeks of the protocol and six subjects completed the entire 6 weeks. Supraphysiological IGF-I concentrations were maintained throughout the study, increasing from 206 micrograms/l in the control period to 849 micrograms/l at the end of 6 weeks of rhIGF-I treatment. The increase in IGF-I levels was accompanied by a significant increase in IGF binding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels of IGF binding protein-1. In summary, IGF-I significantly lowered blood glucose as reflected by short-term and long-term indexes of glycemic control and increased insulin sensitivity. It remains to be determined whether a dosage can be administered that avoids significant side effects and still achieves reasonable glycemic control.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Haluska, H. M. Shaw, G. N. Batzel, D. Yin, J. R. Molina, L. R. Molife, T. A. Yap, M. L. Roberts, A. Sharma, A. Gualberto, et al. Phase I Dose Escalation Study of the Anti Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5834 - 5840. [Abstract] [Full Text] [PDF]

				M J E Walenkamp and J M Wit Genetic disorders in the GH IGF-I axis in mouse and man Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S15 - S26. [Abstract] [Full Text] [PDF]

				D. R. Clemmons, M. Sleevi, G. Allan, and A. Sommer Effects of Combined Recombinant Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein-3 in Type 2 Diabetic Patients on Glycemic Control and Distribution of IGF-I and IGF-II among Serum Binding Protein Complexes J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2652 - 2658. [Abstract] [Full Text] [PDF]

				K. Yoshida, K. Murao, H. Imachi, W. M. Cao, X. Yu, J. Li, R. A. M. Ahmed, N. Kitanaka, N. C. W. Wong, T. G. Unterman, et al. Pancreatic Glucokinase Is Activated by Insulin-Like Growth Factor-I Endocrinology, June 1, 2007; 148(6): 2904 - 2913. [Abstract] [Full Text] [PDF]

				N. R. Poa and P. F. Edgar Insulin Resistance Is Associated With Hypercortisolemia in Polynesian Patients Treated With Antipsychotic Medication Diabetes Care, June 1, 2007; 30(6): 1425 - 1429. [Abstract] [Full Text] [PDF]

				M. J. E. Walenkamp, H. J. van der Kamp, A. M. Pereira, S. G. Kant, H. A. van Duyvenvoorde, M. F. Kruithof, M. H. Breuning, J. A. Romijn, M. Karperien, and J. M. Wit A Variable Degree of Intrauterine and Postnatal Growth Retardation in a Family with a Missense Mutation in the Insulin-Like Growth Factor I Receptor J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3062 - 3070. [Abstract] [Full Text] [PDF]

				P. Pennisi, O. Gavrilova, J. Setser-Portas, W. Jou, S. Santopietro, D. Clemmons, S. Yakar, and D. LeRoith Recombinant Human Insulin-Like Growth Factor-I Treatment Inhibits Gluconeogenesis in a Transgenic Mouse Model of Type 2 Diabetes Mellitus Endocrinology, June 1, 2006; 147(6): 2619 - 2630. [Abstract] [Full Text] [PDF]

				G. Sesti, A. Sciacqua, M. Cardellini, M. A. Marini, R. Maio, M. Vatrano, E. Succurro, R. Lauro, M. Federici, and F. Perticone Plasma Concentration of IGF-I Is Independently Associated With Insulin Sensitivity in Subjects With Different Degrees of Glucose Tolerance Diabetes Care, January 1, 2005; 28(1): 120 - 125. [Abstract] [Full Text] [PDF]

				H. M. Domene, S. V. Bengolea, A. S. Martinez, M. G. Ropelato, P. Pennisi, P. Scaglia, J. J. Heinrich, and H. G. Jasper Deficiency of the Circulating Insulin-like Growth Factor System Associated with Inactivation of the Acid-Labile Subunit Gene N. Engl. J. Med., February 5, 2004; 350(6): 570 - 577. [Full Text] [PDF]

				M. Haluzik, S. Yakar, O. Gavrilova, J. Setser, Y. Boisclair, and D. LeRoith Insulin Resistance in the Liver-Specific IGF-1 Gene-Deleted Mouse Is Abrogated by Deletion of the Acid-Labile Subunit of the IGF-Binding Protein-3 Complex: Relative Roles of Growth Hormone and IGF-1 in Insulin Resistance Diabetes, October 1, 2003; 52(10): 2483 - 2489. [Abstract] [Full Text] [PDF]

				I. Friehs and P. J. del Nido Increased susceptibility of hypertrophied hearts to ischemic injury Ann. Thorac. Surg., February 1, 2003; 75(2): S678 - 684. [Abstract] [Full Text] [PDF]

				K. Sakai, H. B. Lowman, and D. R. Clemmons Increases in Free, Unbound Insulin-like Growth Factor I Enhance Insulin Responsiveness in Human Hepatoma G2 Cells in Culture J. Biol. Chem., April 12, 2002; 277(16): 13620 - 13627. [Abstract] [Full Text] [PDF]

				I. Friehs, C. Stamm, H. Cao-Danh, F. X. McGowan Jr, and P. J. del Nido Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts Ann. Thorac. Surg., November 1, 2001; 72(5): 1650 - 1656. [Abstract] [Full Text] [PDF]

				K. Sjogren, K. Wallenius, J.-L. Liu, M. Bohlooly-Y, G. Pacini, L. Svensson, J. Tornell, O. G.P. Isaksson, B. Ahren, J.-O. Jansson, et al. Liver-Derived IGF-I is of Importance for Normal Carbohydrate and Lipid Metabolism Diabetes, July 1, 2001; 50(7): 1539 - 1545. [Abstract] [Full Text] [PDF]

				S. Yakar, J.-L. Liu, A. M. Fernandez, Y. Wu, A. V. Schally, J. Frystyk, S. D. Chernausek, W. Mejia, and D. Le Roith Liver-Specific igf-1 Gene Deletion Leads to Muscle Insulin Insensitivity Diabetes, May 1, 2001; 50(5): 1110 - 1118. [Abstract] [Full Text]

				D. Le Roith, C. Bondy, S. Yakar, J.-L. Liu, and A. Butler The Somatomedin Hypothesis: 2001 Endocr. Rev., February 1, 2001; 22(1): 53 - 74. [Abstract] [Full Text]

				K. Cusi and R. DeFronzo Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3077 - 3084. [Abstract] [Full Text]

				S. K. Rasmussen, C. Lautier, L. Hansen, S. M. Echwald, T. Hansen, C. T. Ekstrøm, S. A. Urhammer, K. Borch-Johnsen, F. Grigorescu, R. J. Smith, et al. Studies of the Variability of the Genes Encoding the Insulin-Like Growth Factor I Receptor and Its Ligand in Relation to Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1606 - 1610. [Abstract] [Full Text]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				M. Federici, O. Porzio, D. Lauro, P. Borboni, B. Giovannone, L. Zucaro, M. L. Hribal, and G. Sesti Increased Abundance of Insulin/Insulin-Like Growth Factor-I Hybrid Receptors in Skeletal Muscle of Obese Subjects Is Correlated with In Vivo Insulin Sensitivity J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2911 - 2915. [Abstract] [Full Text]

				A. Cittadini, Y. Ishiguro, H. Stromer, M. Spindler, A. C. Moses, R. Clark, P. S. Douglas, J. S. Ingwall, and J. P. Morgan Insulin-like Growth Factor-1 but Not Growth Hormone Augments Mammalian Myocardial Contractility by Sensitizing the Myofilament to Ca2+ Through a Wortmannin-Sensitive Pathway : Studies in Rat and Ferret Isolated Muscles Circ. Res., June 13, 1998; 83(1): 50 - 59. [Abstract] [Full Text] [PDF]

				V. Quarmby, C. Quan, V. Ling, P. Compton, and E. Canova-Davis How Much Insulin-Like Growth Factor I (IGF-I) Circulates? Impact of Standardization on IGF-I Assay Accuracy J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1211 - 1216. [Abstract] [Full Text]

				G. Paolisso, S. Ammendola, A. Del Buono, A. Gambardella, M. Riondino, M. R. Tagliamonte, M. R. Rizzo, C. Carella, and M. Varricchio Serum Levels of Insulin-Like Growth Factor-I (IGF-I) and IGF-Binding Protein-3 in Healthy Centenarians: Relationship with Plasma Leptin and Lipid Concentrations, Insulin Action, and Cognitive Function J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2204 - 2209. [Abstract] [Full Text] [PDF]

				D. Le Roith Insulin-Like Growth Factors N. Engl. J. Med., February 27, 1997; 336(9): 633 - 640. [Full Text] [PDF]